Sherif Raouf1, Gianfilippo Bertelli2, Agnes Ograbek3, Polly Field4, Irwin Tran5. 1. Department of Oncology - Clinical, Queen's Hospital, Rom Valley Way, Romford, RM7 0AG, UK. 2. Department of Oncology, Singleton Hospital, Sketty Lane, Swansea, SA2 8QA, UK. 3. Global Product Development - Medical Affairs Oncology, Roche Products Limited, Hexagon Place, Falcon Way, Shire Park, Welwyn Garden City, AL7 1TW, UK. 4. Value Demonstration Practice, PharmaGenesis Oxford Central, 38 St Aldates, Chamberlain House, Oxford, OX1 1BN, UK. 5. Global Access Department, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
Abstract
AIM: This review aims to assist physicians and payers in assessing the efficacy and safety of bevacizumab in real-world clinical practice by identifying evidence on the comparative effectiveness and safety of bevacizumab in its most frequent indications. Materials & methods: In a systematic review of the published literature, electronic databases (Embase®, MEDLINE® and the Cochrane Library) were searched in May 2016 and updated in January 2017; 20 scientific congresses were searched in 2014-2017. RESULTS: Of 61 included publications, 49, eight, four and 0 concerned metastatic colorectal cancer, metastatic breast cancer, advanced ovarian cancer and cervical cancer, respectively. Fifteen publications (metastatic colorectal cancer) reported on factors predictive of response to therapy. CONCLUSION: Effectiveness findings from real-world studies broadly supported results from registration studies.
AIM: This review aims to assist physicians and payers in assessing the efficacy and safety of bevacizumab in real-world clinical practice by identifying evidence on the comparative effectiveness and safety of bevacizumab in its most frequent indications. Materials & methods: In a systematic review of the published literature, electronic databases (Embase®, MEDLINE® and the Cochrane Library) were searched in May 2016 and updated in January 2017; 20 scientific congresses were searched in 2014-2017. RESULTS: Of 61 included publications, 49, eight, four and 0 concerned metastatic colorectal cancer, metastatic breast cancer, advanced ovarian cancer and cervical cancer, respectively. Fifteen publications (metastatic colorectal cancer) reported on factors predictive of response to therapy. CONCLUSION: Effectiveness findings from real-world studies broadly supported results from registration studies.
Authors: Seung-Seop Yeom; Soo Young Lee; Han Deok Kwak; Chang Hyun Kim; Young Jin Kim; Hyeong Rok Kim Journal: Medicine (Baltimore) Date: 2020-02 Impact factor: 1.817